Application of injection containing small molecular hyaluronic acid

The 10-60KD hyaluronic acid fragment injection prepared through specific production methods solves the problem of unclear function of small molecule hyaluronic acid, realizes the stability of the injection and the treatment effect of various diseases, and meets the clinical indications and Safety requirements.

CN118902993APending Publication Date: 2024-11-08惠觅宙
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410984684.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2016-04-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The functions of existing small molecule hyaluronic acid are not fully defined, and it is difficult to determine its clinical indications and drug properties. In vivo injections may have different effects from in vitro preparations, and they need to meet the requirements of high purity, no allergic reactions and clear indications.

Method used

The injection solution containing 10-60KD hyaluronic acid fragments was prepared by specific production methods. The macromolecule hyaluronic acid was cut by recombinant human hyaluronidase PH20, and inactivate, filter and concentrate to ensure the stability and safety of the injection solution. Suitable for injection of subcutaneous fat layer or pain points in the abdomen.

Benefits of technology

The stable production of small molecule hyaluronic acid injection is achieved, which is used to treat solid tumors, metastasis, recurrence and physical and energy recovery after chemotherapy, showing obvious therapeutic effects and safety, and is suitable for a variety of diseases and disease states.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902993A_ABST
    Figure CN118902993A_ABST
Patent Text Reader

Abstract

The invention discloses an application of an injection containing small molecular hyaluronic acid. The injection is prepared by the following steps: A, producing saccharified recombinant human hyaluronidase PH20 through animal cell or yeast or plant expression; b, preparing a macromolecular hyaluronic acid solution from a macromolecular hyaluronic acid raw material, introducing sodium chloride and magnesium ions, and adding recombinant human hyaluronidase PH20 for cutting to obtain a reaction solution containing hyaluronic acid fragments with the molecular weight of 10-60KD; c, carrying out inactivation treatment on the residual recombinant human hyaluronidase PH20; and D, carrying out bacterium filtration, virus filtration inactivation and ultrafiltration concentration. The injection provided by the invention can be used for treating solid tumors, and has obvious treatment effects on metastasis and recurrence of the solid tumors and physical strength and energy recovery after chemotherapy of the solid tumors.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of application number 201610264221.9, application date 2016.04.25, and invention name “An injection containing small molecule hyaluronic acid and its use”. Technical Field

[0002] The present invention relates to the field of disease treatment drugs, and in particular to the use of an injection containing small molecule hyaluronic acid. Background Art

[0003] Hyaluronic acid, also known as glass acid, uronic acid, and hyaluronic acid, is called hyaluronic acid (HA for short) in English. It is a high-grade polysaccharide composed of D-glucuronic acid and N-acetylglucosamine, and the disaccharide unit can reach 25,000 Da. Human subcutaneous tissue, epidermis, oropharyngeal mucosa and other tissues contain a large amount of macromolecular hyaluronic acid. In other words, macromolecular hyaluronic acid is the basic building material of various tissues such as human skin, mucosa, and subcutaneous tissue, and has the function of water retention and moisturizing. The existing hyaluronic acid products on the market are mainly facial care or facial beauty products with macromolecular hyaluronic acid as the main functional ingredient.

[0004] A series of studies in recent years have shown that small molecule hyaluronic acid and large molecule hyaluronic acid, which are differentiated by molecular weight, show functional differences in small animal experiments and cellular level studies. Mainstream literature shows that small molecule hyaluronic acid is a degradation product of inflammation, consistent with the distribution of inflammation, and its function is to induce and promote inflammatory responses.

[0005] However, the research results of the applicant in recent years (patent application numbers 200780052196.7, 201310325056.X, 201310454955.X, 201410153593.5, 201510065499.9, 201510065498.4, 201510067326.0, 201510333526.6) suggest another possibility, that is, small molecule hyaluronic acid has the function of inhibiting inflammation. These documents suggest that the function of small molecule hyaluronic acid in inhibiting inflammation is related to its production method and the degree of molecular size, and the comparison results of animal experiments and human experiments also suggest that the function of small molecule hyaluronic acid may be completely different in small animals and humans. For example, the above literature shows that small molecule hyaluronic acid (molecular weight 10-60KD) can be made into in vitro preparations for local use (such as daily necessities, sanitary products, cosmetics, skin care products, disinfection products, etc.), which is helpful for treating skin and mucosal inflammation, achieving skin beauty and anti-aging effects, while small molecule hyaluronic acid less than 10KD basically has no such effects. However, the recent patent WO / 2014 / 165713 of CEDARS-SINAI MEDICAL CENTER shows that small molecule hyaluronic acid less than 10KD produced by bacterial streptococci hyaluronidase cleavage does not cause inflammatory response, but small molecule hyaluronic acid greater than 10KD produced by bacterial Streptomyces hyaluronidase does cause inflammatory response, suggesting that the function of small molecule hyaluronic acid may also be related to the type of cleavage enzyme.

[0006] The above contradictory research results suggest that the exact function of small molecule hyaluronic acid fragments is currently difficult to determine, and the production method, molecular weight, type of cleavage enzyme, and method of use of small molecule hyaluronic acid fragments may affect their functional performance. In addition to these known possible factors, there are still many other unknown factors that researchers cannot be sure of. Therefore, although industry professionals place their hopes on the medical value of small molecule hyaluronic acid, it is still difficult to predict the success of clinical research and drugability of small molecule hyaluronic acid, especially the clinical indications. Although our previous research has obtained a feasible and effective small molecule hyaluronic acid in vitro preparation, due to the complex internal environment of the human body, the in vivo injection preparation of small molecule hyaluronic acid may be completely different from the in vitro preparation, and the effect in humans and animals may not be the same. Therefore, it is even more necessary to verify clinical research. In addition, small molecule hyaluronic acid used as an in vivo injection preparation will have higher requirements in at least many aspects, such as high purity, no allergic reaction, clear indications and side effects, and clear injection dose, injection route, injection dose, etc. Solving the above problems has great scientific research significance and commercial value. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide an injection containing small molecule hyaluronic acid with a specific production method.

[0008] In order to solve the above technical problems, the present invention adopts the following technical solutions.

[0009] A use of an injection containing small molecule hyaluronic acid, wherein the use is in the preparation of a medicine for treating solid tumors.

[0010] Furthermore, the invention relates to an application of the invention in the preparation of a drug for treating metastasis and recurrence of solid tumors or in the preparation of a drug for restoring physical strength and energy after chemotherapy of solid tumors.

[0011] Furthermore, the solid tumor is ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, colon cancer, kidney cancer or meningioma.

[0012] Furthermore, the preparation of the injection solution containing small molecule hyaluronic acid comprises the following steps:

[0013] A. Using animal cells, yeast or plants to express and produce saccharified recombinant human hyaluronidase PH20;

[0014] B. preparing a macromolecular hyaluronic acid solution using a macromolecular hyaluronic acid raw material, introducing sodium chloride and magnesium ions, adding the recombinant human hyaluronidase PH20 to cut the macromolecular hyaluronic acid, and obtaining a reaction solution containing hyaluronic acid fragments with a molecular weight of 10-60KD;

[0015] C. inactivating the recombinant human hyaluronidase PH20 remaining in the obtained reaction solution;

[0016] D. Perform bacterial filtration, virus filtration inactivation and ultrafiltration concentration.

[0017] Furthermore, the preparation process also includes a step of removing the inactivated recombinant human hyaluronidase.

[0018] Furthermore, the purity of the saccharified recombinant human hyaluronidase PH20 in step A is >99.0%, and the purity of the macromolecular hyaluronic acid raw material in step B is >99.9%.

[0019] Furthermore, the molecular weight of the macromolecular hyaluronic acid raw material in step B is 800-1200KD; the concentrations of sodium chloride and magnesium ions in the macromolecular hyaluronic acid solution are 80-90mM and 1mM respectively; 20,000 units of the recombinant human hyaluronidase are added per gram of the macromolecular hyaluronic acid raw material, and the enzyme cleavage reaction is carried out at 37 degrees for 6 hours.

[0020] Furthermore, each 2-4 ml of the injection contains 100 mg of the hyaluronic acid fragment and 0-20 ug of the inactivated recombinant human hyaluronidase residue, the concentration of the magnesium ion in the injection is 1 mM, and the concentration of the sodium chloride in the injection is 115-125 mM.

[0021] Furthermore, the injection solution is used by injection into the subcutaneous fat layer of the abdomen or into painful / itchy spots or into diseased areas.

[0022] Furthermore, the injection solution is used in a dosage of 1-2 times a day, and each injection contains 100 mg of the hyaluronic acid fragment with a molecular weight of 10-60 KD.

[0023] Due to the adoption of the above technical solution, the present invention has at least the following advantages:

[0024] The injection of the invention is easy to produce and has a stable preparation, can be used to treat solid tumors, and has obvious therapeutic effects on the metastasis and recurrence of solid tumors and the recovery of physical strength and energy after chemotherapy of solid tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The above is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation methods.

[0026] Figure 1 (a) (b) are the rapid flow animal cell reactor amplification and large-scale culture workshops for producing high-purity glycosylated recombinant human hyaluronidase.

[0027] Figure 2 It is a high-purity glycosylated recombinant human hyaluronidase produced by animal cells (CHO cells).

[0028] Figure 3 It is a preparation form of the injection solution containing small molecule hyaluronic acid described in the present invention.

[0029] Figure 4 The antibacterial effect of hyaluronic acid fragments with molecular weight of 10KD-60KD was shown.

[0030] Figure 5 The results show that the injection of the present invention has anti-inflammatory and antibacterial effects on skin wounds of small animals.

[0031] Figure 6(a)-(e) respectively show the effects of the injection of the present invention on IL-1, IL-6, IFN-β, IFN-α, and IL-10 (Note: LPS=endotoxin; L+A=LPS+anti-human TLR4 single chain antibody; L+HA=LPS+B-HA).

[0032] Figure 7 It is an ophthalmological laboratory diagnosis of subjects with vitreous opacities and vitreous detachment.

[0033] Figure 8 The comparison of photos of some subjects before and after treatment shows the therapeutic effect of injecting the injection of the present invention into the subcutaneous fat layer of the abdomen on human facial beauty and facial anti-aging.

[0034] Fig. 9 The injection of the present invention is effective in treating scars which are continuously thickened, itchy and have chronic inflammatory reactions after extensive burns without skin grafting.

[0035] Fig.10 The invention is the effect of treating neurodermatitis by injecting the injection solution of the invention into the subcutaneous fat layer of the abdomen.

[0036] Fig.11 The invention is the effect of treating psoriasis by injecting the injection solution of the invention into the subcutaneous fat layer of the abdomen. DETAILED DESCRIPTION

[0037] First of all, it should be noted that the existing macromolecular hyaluronic acid injections in the market are mainly used for facial beauty, facial anti-aging and joint cavity injection lubrication of joints. The injection described in the present invention is an injection containing small molecule hyaluronic acid. Based on the research results in the current industry, the exact function of small molecule hyaluronic acid is difficult to determine, and even based on the current scientific experimental results (see the above background technology), there are contradictory functional phenomena, and the mechanism of action of this phenomenon is not yet fully clear, and it may be necessary to limit the production method of small molecule hyaluronic acid to clarify its efficacy. Therefore, the clinical research and commercialization (i.e., drugability) prospects of small molecule hyaluronic acid are also difficult to predict.

[0038] The present invention provides an injection solution containing small molecule hyaluronic acid obtained by a specific production method. Clinical studies have found that the inventors have unexpectedly obtained the use of the injection solution to treat many new indications. This use is reflected through more convenient injection methods such as injection into the subcutaneous fat layer of the abdomen, injection at painful / itchy points, or injection at diseased sites.

[0039] The inventors used the method "outside the instructions" to conduct beauty and anti-aging research on the injection, and surprisingly found that the injection containing small molecule hyaluronic acid of the present invention can not only effectively promote facial beauty and anti-aging through the subcutaneous fat layer of the abdomen, but also surprisingly increase physical strength and energy and reduce subcutaneous fat of the head, face and neck. According to user feedback, the injection of the present invention also shows the effect of rapid analgesia and itching. Even more amazingly, further in-depth research found that the injection of the present invention has the effect of treating a variety of diseases and disease states, including myofasciitis, muscle tendon injuries, painful bone spurs and intervertebral disc Protruding and painful ankylosing spondylitis, vitreous opacities, large-area burn scars with inflammation, itching and pain, traumatic scars, surgical wound scars, abdominal mucosal adhesions and pelvic mucosal adhesions caused by surgery or peritoneal dialysis, endometriosis with dysmenorrhea, itchy neurodermatitis, psoriasis, itchy senile eczema, infantile eczema and herpetiform eczema or dyshidrosis, physical recovery after chemotherapy for solid tumors and prevention of metastasis of solid tumors, functional recovery after cerebral infarction, periodontal disease and oral ulcers, throat diseases, conjunctival diseases, aging and aging-related diseases, coronary heart disease, prevention and treatment of complications after vascular stents and cardiovascular diseases.

[0040] The injection containing small molecule hyaluronic acid described in the present invention is obtained by a specific production method. The small molecule hyaluronic acid is a hyaluronic acid fragment with therapeutic efficacy produced by recombinant human hyaluronidase PH20, sodium ions and magnesium ions activating macromolecular hyaluronic acid; the hyaluronic acid fragment contained in the hyaluronic acid injection has a molecular weight of 10KD-60KD; the hyaluronic acid fragment with a molecular weight of 10KD-60KD is obtained by saccharifying recombinant human hyaluronidase produced by animal cell Chinese hamster ovary cells or yeast or plant expression at 36-37 degrees in the presence of magnesium ions and sodium chloride to cut macromolecular hyaluronic acid for 5-6 hours; the recombinant human hyaluronidase of the injection is heat-inactivated by 80 degrees for 45-60 minutes. To ensure the safety of the preparation, the saccharified recombinant human hyaluronidase PH20 is preferably high-purity (purity>99.0% is preferred), and the purity of the macromolecular hyaluronic acid raw material adopts medical grade purity>99.9% is preferred. In actual production, high-purity raw materials can be used directly, or low-purity saccharified recombinant human hyaluronidase PH20 or macromolecular hyaluronic acid raw materials can be purified before proceeding to subsequent steps. Combined with clinical studies, we found that hyaluronic acid fragments containing recombinant human hyaluronidase residual protein have no allergic reactions or side effects when injected into the subcutaneous fat layer of the abdomen or pain points or diseased areas.

[0041] Further, affinity column chromatography, precipitation, ultrafiltration and dialysis methods are used to separate the inactivated recombinant human hyaluronidase PH20 residual protein, and an injection containing only 10KD-60KD hyaluronic acid fragments, sodium chloride and magnesium ions is obtained. In combination with human clinical studies, we found that injections containing and not containing the inactivated recombinant human hyaluronidase PH20 residual protein in the subcutaneous fat layer or pain point or diseased area have therapeutic effects, no allergic reactions and no side effects, indicating that the hyaluronic acid fragments of 10KD-60KD are the main active ingredients.

[0042] Further, according to the above production method, the injection preparation containing small molecule hyaluronic acid of the present invention can be made into at least the following two preparation forms, one preparation does not contain inactivated recombinant human hyaluronidase PH20 residual protein, and the other contains recombinant human hyaluronidase PH20 residual protein without enzymatic activity. Preferably, in order to make the injection preparation containing recombinant human hyaluronidase PH20 residual protein without enzymatic activity more reliable, the residual protein is controlled to be less than 20 micrograms in actual production.

[0043] As a preferred embodiment, the present invention prepares the following injection 1 (containing 100 mg of hyaluronic acid fragments with a molecular weight of 10KD-60KD and inactivated recombinant human hyaluronidase PH20 residual protein with no enzymatic activity per 2-4 ml, the sodium chloride concentration in the injection is 115-125 mM, and the magnesium ion concentration is 1 mM) and injection 2 (containing 100 mg of hyaluronic acid fragments with a molecular weight of 10KD-60KD per 2-4 ml, the sodium chloride concentration in the injection is 115-125 mM, the magnesium ion concentration is 1 mM, and does not contain recombinant human hyaluronidase PH20 residual protein with no enzymatic activity per 2-4 ml) according to the above two preparation forms. The injection can be stable for 2 years when stored at 4 to 12 degrees or -8 to -70 degrees and room temperature.

[0044] Further clinical verification of the above two preparations found that the injection solution was injected subcutaneously or at painful / itchy points or at diseased sites, 1-2 times a day, and each injection solution contained 100 mg of the hyaluronic acid fragment. It was convenient and effective, without side effects and allergic reactions, and could be used to prepare biological drugs and Class 3 medical devices.

[0045] The present invention is described below by means of specific embodiments. It should be understood that the embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0046] Example 1

[0047] Objective: To study the production process of injection, and to manufacture injection with and without recombinant human hyaluronidase PH20 residual protein.

[0048] Method: animal cells (CHO cells) are used to produce glycosylated recombinant human hyaluronidase PH20, including: artificially synthesizing the gene cDNA of the glycosylated recombinant human hyaluronidase PH20, inserting it into the GC-rich pMH3, pMH4, pMH5 empty expression vectors to construct pMH3-PH20, pMH4-PH20, pMH5-PH20 expression vectors (here, the technology recorded in the patent document with announcement number CN102124019A is used to construct the expression vector so as to highly express the recombinant protein); then the cDNA expression vectors of pMH3-PH20, pMH4-PH20, pMH5-PH20 are transferred into CHO-S cell lines, and the CHO-S cell lines with high expression of PH20 are screened, and then the cDNA expression vectors of pMH3-PH20, pMH4-PH20, and ... cDNA expression vectors of pMH3-PH20, pMH4-PH20, and pMH5-PH20 are transferred into CHO-S cell lines, and the cDNA expression vectors of pMH3-PH20, pMH4-PH20, and pMH5-PH20 are transferred into CHO-S cell lines, and the cDNA expression vectors of pMH3-PH20, pMH4-PH20, and pMH5-PH20 are Figure 1 The torrent-type animal cell reactor shown in the figure is enlarged and cultured on a large scale; the harvest liquid containing PH20 is filtered at 0.22um and then separated by 2-3 steps such as ion column, and then filtered by bacteria and viruses for inactivation, ultrafiltration and concentration to make Figure 2 The purity shown is >99.0% sterile, virus-free, glycosylated recombinant human hyaluronidase PH20.

[0049] Prepare an injection-grade hyaluronic acid raw material or hyaluronic acid injection solution with a molecular weight of 800-1200KD or purify a non-injection-grade hyaluronic acid raw material with a molecular weight of 800-1200KD to an injection-grade hyaluronic acid raw material; add the injection-grade hyaluronic acid raw material with a molecular weight of 800-1200KD to injection-grade pure water once or several times, and then add 80-90mM sodium chloride, 1mM magnesium ion, and 20,000 units (about 20 micrograms) of recombinant human hyaluronidase per gram of hyaluronic acid in sequence, mix well, and react at 37 degrees for 6 hours until the molecular weight of the hyaluronic acid fragment reaches To 10KD-60KD, add 35-45mM sodium chloride to adjust the osmotic pressure to 280-300 milliosm / liter (mOsm / L), and then heat at 80 degrees for 45-60 minutes, filter bacteria and viruses to inactivate, and concentrate by ultrafiltration to prepare hyaluronic acid injection 1 (each 2-4 ml contains 100mg of hyaluronic acid fragments with a molecular weight of 10KD-60KD, and also contains less than 20ug of recombinant human PH20 hyaluronidase residues without hyaluronic acid degradation activity, the sodium chloride concentration in the injection is 115-125mM, the magnesium ion concentration is 1mM,). The recombinant human hyaluronidase residual protein of the hyaluronic acid fragment injection containing recombinant human hyaluronidase residual protein is removed by using recombinant human hyaluronidase affinity column chromatography, column chromatography, precipitation, dialysis, ultrafiltration concentration, etc. in sequence or separately to produce a hyaluronic acid injection 2 that does not contain recombinant human hyaluronidase residual protein (each 2-4 ml contains 100 mg of hyaluronic acid fragments with a molecular weight of 10KD-60KD, and the sodium chloride content in the injection is 115-125mM and the magnesium ion content is 1mM).

[0050] result:

[0051] Figure 2 The electrophoresis diagram is of glycosylated recombinant human hyaluronidase produced by animal cells (CHO cells) with a purity of >99%;

[0052] The preparations of hyaluronic acid injection 1 and hyaluronic acid injection 2 were manufactured as follows:

[0053] Hyaluronic acid injection 1: 100mg / 2ml of hyaluronic acid fragments with a molecular weight of 10KD-60KD, 115-125mM sodium chloride, 1mM magnesium ion, and less than 20ug of residual protein of recombinant human PH20 hyaluronidase with no activity of degrading hyaluronic acid (endotoxin less than 0.5IU / ml, sterile, and virus-free).

[0054] Hyaluronic acid injection 2: 100 mg / 2 ml of hyaluronic acid fragments with a molecular weight of 10KD-60KD, 115-125 mM sodium chloride, 1 mM magnesium ion (endotoxin less than 0.5 IU / ml, sterile, virus-free).

[0055] Conclusion: The results showed that hyaluronic acid injection with and without recombinant human hyaluronidase residual protein was successfully manufactured. Figure 3 ) and injection 2, clarify the production process of injection.

[0056] Example 2

[0057] Objective: To study the anti-inflammatory and antibacterial effects of hyaluronic acid injection 1 in Example 1 through in vitro experiments, molecular cytology experiments, and small animal experiments.

[0058] Method: The hyaluronic acid injection 1 of Example 1 was diluted 1-fold with physiological saline, and in vitro antibacterial experiments, molecular cytology experiments, and small animal experiments were performed to detect the anti-inflammatory and antibacterial effects of the hyaluronic acid injection.

[0059] result: Figure 4 It showed that hyaluronic acid injection inhibited the growth of Porphyromonas gingivalis clones in in vitro experiments, suggesting that hyaluronic acid injection materials are not conducive to the growth of Porphyromonas gingivalis (Note: the negative control is normal saline, and the positive control is the antibiotic metronidazole); Figure 5 Demonstrate the anti-inflammatory and antibacterial effects of hyaluronic acid injection on skin wounds of small animals; Figure 6It was shown that hyaluronic acid injection promoted the secretion of IL-10 by human TLR4 receptor-positive cells, and inhibited the secretion of TNF, IL-1, IL-6 and interferon beta caused by endotoxin (Note: LPS = endotoxin; L + A = LPS + anti-human TLR4 single chain antibody; L + HA = LPS + B-HA). Combined with literature research, an article (Cuixia Yang, Manlin Cao, Hua Liu, Yiqing He, Jing Xu, Yan Du, Yiwen Liu, Wenjuan Wang, Lian Cui, Jiajie Hu, Feng Gao, The high and low molecular weight forms of hyaluronan have distinct effects on CD44 Clustering, Published on November 1, 2012 as Manuscript M112.349209) showed that CD44 receptor may also be involved in the mechanism of action of hyaluronic acid injection.

[0060] Conclusion: Hyaluronic acid injection has obvious anti-inflammatory and antibacterial effects on human cells and small animal skin wounds. Its anti-inflammatory and antibacterial effects may be achieved through multiple pathways, including endotoxin receptors, beta-defensin secretion, and CD44-mediated inflammatory cell migration and aggregation.

[0061] Example 3

[0062] Objective: To study the anti-aging effects and safety of two hyaluronic acid injections containing (experimental group 1) and not containing (experimental group 2) hyaluronic acid fragments of recombinant human hyaluronidase PH20 residual protein in Example 1 above on human facial beauty.

[0063] Methods: A hyaluronic acid fragment injection containing recombinant human hyaluronidase PH20 residual protein (100 mg of hyaluronic acid fragments with a molecular weight of 10KD-60KD, 115-125 mM sodium chloride, 1 mM magnesium ion, and less than 20 micrograms of recombinant human hyaluronidase residual protein without hyaluronic acid degradation activity) was used as experimental group 1. A clinical study was conducted on 38 subjects (average age 61±26 years, 20 males and 18 females) who were prone to various diseases or subclinical problems or aging and aging-related diseases in China's current air pollution, drinking water pollution and work pressure environment; a hyaluronic acid injection without recombinant human hyaluronidase residual protein was used as experimental group 1. Hyaluronic acid fragment injection (100 mg of hyaluronic acid fragment with a molecular weight of 10KD-60KD, 115-125 mM sodium chloride and 1 mM magnesium ion) was used as experimental group 2, 100 mg each time (referring to 100 mg of hyaluronic acid fragment with a molecular weight of 10KD-60KD contained in the injection, the same below) was injected into the subcutaneous fat layer of the abdomen, 1-2 times a day, and the injection was continuously injected for at least 7 days. A clinical study was conducted on 38 subjects (average age 62±21 years old, 19 males and 19 females) who were prone to various diseases or subclinical problems or aging and aging-related diseases in China's current air pollution, drinking water pollution and work pressure environment;

[0064] The cosmetic effects of the two injections were compared by facial observation or photograph comparison and scoring before and after treatment (scoring: ineffective, uncertain, and obviously effective). The safety of the injections was evaluated by doctors asking the subjects about their feelings, symptoms, physical examinations, and laboratory tests, that is, the presence or absence of side effects, including pain at the injection site, physical discomfort before and after injection, energy and physical condition, original body pain, original body diseases, and changes in various subclinical problems.

[0065] result:

[0066] Table 1: Effects of two injections on facial beauty and anti-aging

[0067] invalid Unsure Clearly effective Number of samples Experimental Group 1 0 0 38 38 Experimental Group 2 0 0 38 38

[0068] Figure 8 The comparison of photos of some subjects before and after treatment shows the therapeutic effect of hyaluronic acid injection on human facial beauty and facial aging. It also shows that hyaluronic acid injection can significantly reduce the thickness of subcutaneous fat tissue in the head, face, neck, shoulders, back, abdomen, upper and lower limbs through injection into the subcutaneous fat layer of the abdomen.

[0069] Table 2: Effects of two injections on reducing subcutaneous fat

[0070] invalid Unsure Clearly effective Number of samples Experimental Group 1 2 6 30 38 Experimental Group 2 1 6 31 38

[0071] Table 3: Presence or absence of pain, local swelling, local and systemic allergies after deep injection of the two injections into the subcutaneous fat layer of the abdomen

[0072] none Unsure have Number of samples Experimental Group 1 38 0 0 38 Experimental Group 2 38 0 0 38

[0073] In addition to the above cosmetic effects, safety and side effects, we also found that 3 subjects felt uncomfortable and sleepy after injection in the subcutaneous fat layer of the abdomen due to fatigue; the drowsiness lasted for 0.5-1.5 hours, one of whom took a 1.0 hour nap after the first injection and had significantly increased mental and physical strength after waking up; the other two subjects no longer felt drowsy after two injections.

[0074] Table 4: Side effects of drowsiness after injection of the two injections

[0075] none Unsure have Number of samples Experimental Group 1 36 0 2 38 Experimental Group 2 37 0 1 38

[0076] Unexpectedly, 71 out of 76 subjects felt an increase in energy and strength 30 minutes after injection into the subcutaneous fat layer of the abdomen, which was manifested by a willingness to talk, wash dishes, cook, take a walk, plan trips, work, and not want to rest, which lasted for 3-4 days.

[0077] Table 5: Effects of two injections on increasing mental and physical strength

[0078] none Unsure Obviously Number of samples Experimental Group 1 0 3 35 38 Experimental Group 2 0 2 36 38

[0079] Twenty-seven of the 76 subjects (including 20 subjects in experimental group 1 and 17 subjects in experimental group 2) had different pains in shoulders, back, waist, legs and arms. Unexpectedly, they all felt pain relief 30 minutes after injection in the subcutaneous fat layer of the abdomen. Among them, 9 subjects received additional 50 mg injection at the local painful area, and pain relief began to appear 2 minutes after the injection, which was comparable to the effect of local lidocaine mixed with prednisone injection blockade treatment reported by 4 of the subjects.

[0080] Table 6: Analgesic effect of hyaluronic acid injection

[0081]

[0082] 33 out of 76 subjects (including 17 subjects in experimental group 1 and 16 subjects in experimental group 2) experienced varying degrees of pruritus. Unexpectedly, the pain was alleviated or disappeared one day after the injection into the subcutaneous fat layer of the abdomen.

[0083] Table 7: Antipruritic effect of hyaluronic acid injection

[0084]

[0085]

[0086] in conclusion:

[0087] 1. Both hyaluronic acid injections containing hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase have the effects of facial beauty and anti-aging.

[0088] 2. Both injections of hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase significantly reduced the thickness of subcutaneous fat tissue in the head, face, neck, shoulder, back, abdomen, and upper and lower limbs.

[0089] 3. Both injections of hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase were injected into the subcutaneous fat layer of the abdomen. No pain, local redness and swelling, local and systemic allergies were observed after skin injection, and they are easy to use.

[0090] 3. The two injection solutions of hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase were injected into the subcutaneous fat layer of the abdomen. The patients felt comfortable, sleepy and wanted to sleep after the first injection, with an incidence rate of less than 4.0%.

[0091] 4. Unexpectedly, two injection solutions of hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase had a significant effect of increasing energy and physical strength when injected into the subcutaneous fat layer of the abdomen.

[0092] 5. Unexpectedly, two injection solutions of hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase had rapid and significant analgesic effect when injected into the subcutaneous fat layer of the abdomen.

[0093] 6. Unexpectedly, two injection solutions of hyaluronic acid fragments containing and not containing residual protein of recombinant human hyaluronidase had obvious antipruritic effect when injected into the subcutaneous fat layer of the abdomen.

[0094] Example 4

[0095] Objective: To further analyze the changes in diseases and subclinical problems suffered by 76 subjects in Example 3 before and after treatment with hyaluronic acid injection, and to clarify new clinical indications for hyaluronic acid injection.

[0096] Methods: The changes in diseases and subclinical problems suffered by 76 subjects in Example 3 before and after treatment with hyaluronic acid injection were further analyzed, including pre-injection medical history, laboratory test results and changes after injection, to identify possible new clinical indications for hyaluronic acid injection.

[0097] result:

[0098] 1. Rapid and effective treatment of myofasciitis and old sports injuries: Myofasciitis and old sports injuries are sports injuries and senile degenerative diseases. The pathogenesis is not fully understood. There are professional chiropractors in the United States who specialize in treating this disease, but there is currently no cure.

[0099] We analyzed 76 subjects with myofasciitis of the lower back, neck, and upper and lower limbs (4 in experimental group 1 and 3 in experimental group 2) and 4 with old sports injuries (2 in experimental group 1 and 2 in experimental group 2). The results are shown in Table 8:

[0100] Table 8: Effect of hyaluronic acid injection in the treatment of myofasciitis and old sports injuries

[0101]

[0102] Among them, a 57-year-old male subject suffered from old sports injuries for 17 years and neck and back myofasciitis for 3 years. The pain was very torturous every year when the weather was cold. Certain muscle movements would also cause pain, and the range of motion of the neck and back was limited. After a 100mg injection in the subcutaneous fat layer of the abdomen for 30 minutes, the pain was relieved. Later, a 100mg deep injection at the local pain point of the neck and back had a better effect. After injecting 15x100mg within 2 months, the pain point nodules on the back disappeared, the thickness of the neck and back muscles was significantly thinned, and there was no recurrence in 12 months. The results show that in addition to pain relief, hyaluronic acid injection ultimately solved the inflammatory lesions of old sports injuries and myofasciitis, and achieved the purpose of muscle and myofascial regeneration.

[0103] 2. Hyaluronic acid injection is a fast and effective treatment for bone spurs, intervertebral disc herniation or lumbar and cervical spondylosis: Bone spurs, intervertebral disc herniation or lumbar and cervical spondylosis is a degenerative disease related to sports injuries in the elderly. The pathogenesis is not fully understood and there is no cure. We analyzed 11 subjects with lumbar and cervical bone hyperplasia and bone spurs among 76 subjects (6 cases in experimental group 1 and 5 cases in experimental group 2). The results are shown in Table 9:

[0104] Table 9: Effect of hyaluronic acid injection on the treatment of bone spurs, disc herniation or lumbar and cervical spondylosis

[0105]

[0106] One of the subjects, a 57-year-old female, had suffered from lumbar and cervical bone hyperplasia and bone spurs for 14 years. The pain was very torturous, and certain muscle movements would also cause pain. The range of motion of the neck and back was limited, and the upper limbs were numb and the work ability was reduced. One day after the injection of 100mg in the subcutaneous fat layer of the abdomen, the patient reported that the pain was reduced by more than 50%, and she was able to go to the kitchen to make dumplings and cook; the next day, after the injection of 100mg, the patient reported that the pain was reduced by more than 80%; the third day, after the injection of 100mg, the patient reported that the pain was reduced by more than 95%. After the injection of 15x100mg within 2 months, there was no recurrence in 2 months. The results show that in addition to relieving pain, hyaluronic acid injection eventually began to reorganize and regenerate the inflammatory lesions of old injuries.

[0107] Another 57-year-old female subject suffered from cervical bone hyperplasia and bone spurs for 4 years. The range of motion of the neck and back was limited, and the pain was excruciating and there was facial numbness. Certain muscle movements would also cause pain, numbness of the upper limbs and decreased work ability. One day after the injection of 100mg in the subcutaneous fat layer of the abdomen, the self-reported pain was reduced by more than 50%; the next day after the injection of 100mg, the self-reported pain was reduced by more than 80%. There was no recurrence in 2 months after the injection of 15x100mg within 2 months, indicating that the hyaluronic acid injection, in addition to pain relief, also started the reorganization and regeneration process of the inflammatory lesions of the old injuries. Note: All the above subjects continued treatment and waited for the results of recurrence or no recurrence for more than 6 months.

[0108] 3. Hyaluronic acid injection quickly and effectively treats vitreous opacities: Vitreous opacities are an elderly degenerative disease with an unknown pathogenesis and no effective treatment. Vitreous opacities, also known as floaters, further develop into vitreous detachment, damaging the fundus and affecting vision. We analyzed 9 subjects with vitreous opacities and vitreous detachment among 76 subjects (4 in experimental group 1 and 5 in experimental group 2), and the results are shown in Table 10:

[0109] Table 10: Effect of hyaluronic acid injection on vitreous opacity and vitreous detachment

[0110]

[0111] A 61-year-old female subject, Figure 7 The subject was diagnosed with vitreous opacity and vitreous detachment in the laboratory. Due to the need for facial cosmetic treatment, he received 100 mg of hyaluronic acid injection in the subcutaneous fat layer of the abdomen. On the second day after the injection, it was found that the eye vision improved by chance, and on the third day, the eye floaters became smaller; 15x100 mg was continued to be injected every three days, and the vision continued to improve (from 0.2 to 0.5) and the floaters continued to become thinner and lighter, and there was no obvious recurrence within two months. The above results show that hyaluronic acid injection is surprisingly fast and effective in treating vitreous opacity (floaters) and vitreous detachment.

[0112] 4. Hyaluronic acid injection for the treatment of wound scars with itching (chronic inflammation) and pain (inflammatory pain): Minor wounds in people with scar-prone constitutions can gradually form large scars that continue to thicken and itch. The goal of treatment is to stop itching and reduce scar thickening. Scars formed without skin grafting after large-area burns continue to thicken, itch and have chronic inflammatory reactions ( Fig. 9 ), the treatment goal is to stop itching, eliminate inflammation and reduce scar thickening; surgical wounds are mainly red, swollen, painful, inflammatory reactive exudate and secondary infection, and the treatment goal is to accelerate healing and reduce scar formation. We analyzed 8 subjects (4 in experimental group 1 and 4 in experimental group 2) with wound scars of 76 subjects with itching (chronic inflammation) and pain (inflammatory pain), and the results are shown in Table 11:

[0113] Table 11: Effect of hyaluronic acid injection on wound scars with itching (chronic inflammation) and pain (inflammatory pain)

[0114]

[0115] A 63-year-old woman had extensive burns on her lower limbs 12 years ago, without skin grafting, severe itching, difficulty falling asleep, and inflammation around the scar. After 2x100mg of hyaluronic acid injection for 3 consecutive days, the scar became thinner, the inflammation around the scar disappeared, the itching was significantly reduced, and the pain was significantly reduced; after 30x100mg of hyaluronic acid injection, the scar and surrounding skin were significantly improved, including thinning of the scar, disappearance of inflammation, and reduction of itching, but it did not completely disappear ( Fig. 9 ).

[0116] 5. Hyaluronic acid injection quickly and effectively treats abdominal mucosal adhesions caused by surgery or peritoneal dialysis: Surgical injuries, peritoneal dialysis, etc. almost all cause inflammation and adhesions of the abdominal mucosa, which can cause symptoms and pathological changes depending on the severity, including abdominal pain, abdominal tenderness, abdominal mass and intestinal obstruction. At present, there is no feasible way to eradicate abdominal adhesions. We analyzed 3 subjects with abdominal mucosal adhesions after surgery or dialysis among 76 subjects (1 case in experimental group 1 and 2 cases in experimental group 2), and the results are shown in Table 12:

[0117] Table 12: Hyaluronic acid injection is a rapid and effective treatment for peritoneal adhesions caused by surgery or peritoneal dialysis

[0118]

[0119]

[0120] A 43-year-old woman had a subtotal gastrectomy and peripheral lymph node clearance one month after she started to eat a non-liquid diet. She found a hard mass and pain in her abdomen, vomited after eating, and became severely emaciated and weak. She was clinically diagnosed with intestinal obstruction caused by abdominal adhesions. After 5x100mg of hyaluronic acid was injected into the subcutaneous fat layer of the abdomen, all the above symptoms and signs disappeared. After eating a non-liquid diet, there was no recurrence of intestinal obstruction, and her mental state improved significantly. The treatment results showed that hyaluronic acid injection treatment may have achieved the elimination of abdominal adhesion symptoms and signs by reducing inflammation in the abdominal mucosa.

[0121] VI. Treatment of endometriosis or pelvic mucosal adhesions with dysmenorrhea with hyaluronic acid injection: Endometriosis is often accompanied by infertility and dysmenorrhea; infertility and dysmenorrhea may be related to pelvic mucosal inflammation and adhesions; there is no effective method for treating dysmenorrhea and endometriosis or pelvic mucosal adhesions; we analyzed 3 subjects with pelvic mucosal adhesions and dysmenorrhea among 76 subjects (2 subjects in experimental group 1 and 1 subject in experimental group 2), and the results are shown in Table 13:

[0122] Table 13: Hyaluronic acid injection for the treatment of endometriosis or pelvic mucosal adhesions with dysmenorrhea

[0123]

[0124] The above results show that hyaluronic acid injection significantly alleviates dysmenorrhea, indicating that hyaluronic acid injection reduces the degree of inflammation of endometriosis in the pelvic cavity and the degree of referred pain caused by pelvic adhesions, suggesting that hyaluronic acid injection may also be used to treat infertility caused by poor fallopian tube peristalsis caused by endometriosis and pelvic adhesions.

[0125] VII. Treatment of itchy neurodermatitis, psoriasis, itchy senile eczema, herpetiform eczema or dyshidrosis with hyaluronic acid injection: We analyzed 19 subjects (9 cases in experimental group 1 and 10 cases in experimental group 2) with neurodermatitis, psoriasis, itchy senile eczema, herpetiform eczema or dyshidrosis among 76 subjects, and the results are shown in Table 14:

[0126] Table 14: Effect of hyaluronic acid injection in the treatment of pruritic neurodermatitis and psoriasis

[0127]

[0128]

[0129] One of the neurodermatitis subjects in Table 14 (male, 57 years old) had neurodermatitis for 8 years, with bilateral symmetrical multiple skin lesions, severe itching and local skin inflammatory lesions. He was previously treated with Stelara (anti-IL-12 / 23 antibody) injection, but the effect was not satisfactory to the subject. After hyaluronic acid injection 20x100mg was injected into the subcutaneous fat layer of the abdomen, the itching basically disappeared and the skin inflammatory lesions basically recovered ( Fig.10 ), and the subjects were satisfied with the results.

[0130] One of the psoriasis subjects in Table 14 (male, 52 years old) had psoriasis for 18 years, with multiple localized inflammatory lesions and thickening of the lesions on the abdomen, upper limbs and lower limbs, accompanied by itching symptoms. Two years ago, Stelara (anti-IL-12 / 23 antibody) was used for injection treatment, but the subject was not satisfied with the effect. After hyaluronic acid injection 10x100mg was injected into the subcutaneous fat layer of the abdomen, the itching basically disappeared, the thickened lesions were significantly thinned, and the inflammatory lesions of the skin were significantly restored ( Fig.11 ), and the subjects were satisfied with the results.

[0131] Table 15: Effect of hyaluronic acid injection in the treatment of senile eczema and eczema herpetiformis or dyshidrosis with itching

[0132]

[0133] One of the dyshidrosis subjects (female, 33 years old) in Table 15 had dyshidrosis for 9 years, with onset every summer. After hyaluronic acid injection 20x100mg was injected into the subcutaneous fat layer of the abdomen, dyshidrosis did not occur again during the injection period and 1 year after the injection.

[0134] The results in Tables 14 and 15 indicate that injection of hyaluronic acid injection into the subcutaneous fat layer of the abdomen can effectively treat pruritic neurodermatitis, psoriasis, pruritic senile eczema, herpetiform eczema or dyshidrotic eczema.

[0135] 8. Hyaluronic acid injection for rapid treatment of periodontitis, oral ulcers, pharyngitis, and conjunctival inflammation: Periodontitis, oral ulcers, pharyngitis, and conjunctival inflammation are common in the elderly and are aging-related diseases. They are also related to China's current air pollution, drinking water pollution, and high-pressure work environment. We analyzed a total of 26 subjects with periodontitis, oral ulcers, pharyngitis, and conjunctival inflammation among 76 subjects (16 in experimental group 1 and 10 in experimental group 2), and the results are shown in Table 16:

[0136] Table 16: Effects of hyaluronic acid injection on periodontitis, oral ulcers, pharyngitis, and conjunctival inflammation

[0137]

[0138]

[0139] The results in Table 16 indicate that hyaluronic acid injection has a faster effect in treating periodontitis, oral ulcers, pharyngitis, and conjunctival inflammation than our previous topical use of hyaluronic acid injection spray.

[0140] IX. Hyaluronic acid injection is effective in treating ankylosing spondylitis: Ankylosing spondylitis is a disease with inflammatory pain and severe spinal deformation. We analyzed 2 subjects with ankylosing spondylitis among 76 subjects (1 in experimental group 1 and 1 in experimental group 2), and the results are shown in Table 17:

[0141] Table 17: Effect of hyaluronic acid injection in the treatment of ankylosing spondylitis

[0142]

[0143] Ankylosing spondylitis is a disease with inflammatory pain. The analgesic effect of hyaluronic acid injection treatment indicates that the inflammation of ankylosing spondylitis has been reduced or eliminated, suggesting that the severe spinal deformation caused by inflammation will not continue to develop.

[0144] 10. Hyaluronic acid injection for physical recovery and prevention of solid tumor metastasis after chemotherapy: We analyzed 4 subjects (4 subjects in experimental group 1 and 4 subjects in experimental group 3) who needed physical recovery and prevention of solid tumor metastasis after chemotherapy for solid tumors among 76 subjects. The results are shown in Table 18:

[0145] Table 18: Effect of hyaluronic acid injection on physical recovery and prevention of solid tumor metastasis after chemotherapy

[0146]

[0147]

[0148] Pancreatic head cancer is a very malignant tumor that develops rapidly after metastasis and can lead to death within 90 days at the fastest. Foreign studies have shown that inflammation may be an important factor in the development and metastasis of pancreatic head cancer. The subject (male, 46 years old) in Table 18 was found to have jaundice after chemotherapy for pancreatic head cancer. The pancreatic head cancer metastasized to the liver and blocked the bile duct, causing jaundice. The jaundice problem was solved by surgical placement of a stent and nasobiliary drainage. He underwent chemotherapy every month and received Chinese medicine treatment at the same time. After hyaluronic acid injection 5x100mg was injected into the subcutaneous fat layer of the abdomen, physical strength and energy were restored; after hyaluronic acid injection 20x100mg was injected into the subcutaneous fat layer of the abdomen, ultrasound examination showed that the pancreatic head cancer and the mass metastasized to the liver began to shrink, and the subject patient worked normally for more than 90 days. The above results show that hyaluronic acid injection can promote the recovery of physical strength and energy after chemotherapy for solid tumors and may prevent the development and further metastasis of pancreatic head cancer by inhibiting inflammation. Foreign reports (Halozyme Receives Orphan Drug Designation ForPEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer at: http:

[0149] / / www.halozyme.com / Investors / News-Releases / News-Release-Details / 2014 / Hal ozyme-Receives-Orphan-Drug-Designation-For-PEGylated-Recombinant-Human-Hyaluronidase-PH20-For-Pancreatic-Cancer / default.aspx#sthash.aLjvxToQ.dp uf) The long-acting hyaluronidase PEGPH20 combined with chemotherapy effectively prolongs the survival time of patients with pancreatic ductal carcinoma. Its mechanism of action may be to utilize hyaluronic acid in the human body to produce an injection solution containing small molecule hyaluronic acid similar to the present invention.

[0150] The subject (female, 62 years old) after surgery and chemotherapy for ovarian cancer in Table 18 was extremely weak and bedridden for 24 hours due to chemotherapy and radiotherapy for lymph node metastasis. Hyaluronic acid injection 20x100mg was injected into the subcutaneous fat layer of the abdomen, and physical strength began to recover the next day after injection of 1x100mg. After all 20x100mg were injected, CA125 surprisingly dropped from 500U / ml before treatment to 50U / ml, and the tumor and metastasis mass shrank, indicating that hyaluronic acid injection can promote physical strength recovery after chemotherapy for ovarian cancer and may prevent the development and further metastasis of ovarian cancer by inhibiting inflammation.

[0151] The 64-year-old female subject in Table 18 was diagnosed with right lung cancer, with metastasis to the left lung, brain, bone, and mediastinal lymph nodes. Surgical resection was no longer possible, so radiotherapy and Tarceva chemotherapy were used. The subject was weak after radiotherapy and chemotherapy, and hyaluronic acid injection 10x100mg was injected into the subcutaneous fat layer of the abdomen. Physical strength and energy began to recover on the first day after the injection of 1x100mg. After the injection of all 10x100mg, CT examination revealed that the tumor and metastatic masses were reduced, indicating that hyaluronic acid injection can promote physical strength recovery after radiotherapy and chemotherapy for lung cancer, and may also prevent the development and further metastasis of lung cancer by inhibiting inflammation.

[0152] XI. Treatment of postoperative recurrence of meningioma with hyaluronic acid injection: We analyzed 2 subjects with postoperative recurrence of meningioma among 76 subjects (1 in experimental group 1 and 1 in experimental group 2). The results are shown in Table 19:

[0153] Table 19: Effect of hyaluronic acid injection in treating postoperative recurrence of meningioma

[0154]

[0155] A female subject (61 years old) in Table 19 was diagnosed with meningioma by CT in 2007 due to frequent headaches. After surgery in the same year, the headache disappeared. Headaches began to occur frequently in 2015, and were diagnosed as recurrence of meningioma by CT, that is, the meninges were significantly thickened. Hyaluronic acid injection was injected into the subcutaneous fat layer of the abdomen at 15x100mg, and the headache attacks were reduced and finally completely stopped. The CT examination results showed that the previously proliferated meninges were significantly thinned, and there was no headache attack 90 days after treatment. The above results show that hyaluronic acid injection can be used to treat meningioma or recurrence of meningioma after surgery.

[0156] 12. Hyaluronic acid injection for functional recovery after cerebral embolism: We analyzed 4 subjects (1 in experimental group 1 and 3 in experimental group 2) who needed functional recovery after cerebral embolism among 76 subjects. The results are shown in Table 20:

[0157] Table 20: Effect of hyaluronic acid injection on functional recovery after cerebral embolism

[0158]

[0159] A male subject (67 years old) in Table 20 had half body weakness and difficulty walking 30 days after cerebral embolism. After 10x100mg of hyaluronic acid injection was injected into the subcutaneous fat layer of the abdomen, the weakness of half body improved significantly and he could walk more powerfully, indicating that hyaluronic acid injection can be used for functional recovery after cerebral embolism.

[0160] Another male subject (59 years old) in Table 20 had impaired vision 4 days after cerebral embolism and could only see objects within 20 cm. After hyaluronic acid injection 10x100 mg was injected into the subcutaneous fat layer of the abdomen, his vision improved significantly and he could see objects within 40 cm, indicating that hyaluronic acid injection can be used for functional recovery after cerebral embolism.

[0161] 13. Hyaluronic acid injection for coronary heart disease, prevention of complications after vascular stenting and prevention of cardiovascular disease: Coronary heart disease, complications after vascular stenting and other cardiovascular diseases may be chronic inflammatory diseases in nature, and effective prevention and treatment methods are urgently needed. We analyzed 6 subjects with coronary heart disease and complications after vascular stenting among 76 subjects (3 cases in experimental group 1 and 3 cases in experimental group 2), and the results are shown in Table 21:

[0162] Table 21: Effects of hyaluronic acid injection in treating coronary heart disease, preventing complications after vascular stenting, and preventing cardiovascular diseases

[0163]

[0164] The results in Table 21 indicate that hyaluronic acid injection can be used to treat coronary heart disease, prevent complications after vascular stenting, and may have the effect of preventing cardiovascular disease.

[0165] in conclusion:

[0166] 1. Hyaluronic acid injection is injected into the subcutaneous fat layer of the abdomen or into the painful area or the diseased area to treat painful myofasciitis of the waist, back, neck and shoulder and muscle tendon injuries;

[0167] 2. Hyaluronic acid injection is injected into the subcutaneous fat layer of the abdomen or into the painful area or diseased area to treat painful bone hyperplasia, bone spurs, and intervertebral disc herniation;

[0168] 3. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to treat painful ankylosing spondylitis;

[0169] 4. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to treat floaters or vitreous opacities and the vitreous detachment and decreased vision caused by them;

[0170] 5. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to treat large-area burns, traumatic scars, and surgical scars with inflammation, itching, and pain;

[0171] 6. Hyaluronic acid injection is injected into the subcutaneous fat layer of the abdomen or used in the diseased area to treat abdominal mucosal adhesion and pelvic mucosal adhesion caused by surgery and peritoneal dialysis;

[0172] 7. Hyaluronic acid injection is injected into the subcutaneous fat layer of the abdomen to treat endometriosis with dysmenorrhea;

[0173] 8. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to treat itchy neurodermatitis, psoriasis, itchy senile eczema and herpetiform eczema or sweat herpes;

[0174] 9. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to restore physical strength and energy after chemotherapy of solid tumors and prevent metastasis of solid tumors;

[0175] 10. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to promote functional recovery after cerebral infarction;

[0176] 11. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to quickly treat periodontal disease and oral ulcers, including periodontal disease and oral ulcers caused by chemotherapy and aging;

[0177] 12. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to quickly treat throat diseases, including those caused by chemotherapy and aging;

[0178] 13. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to quickly treat conjunctival diseases, including those caused by chemotherapy and aging;

[0179] 14. Hyaluronic acid injection is injected through the subcutaneous fat layer of the abdomen to treat coronary heart disease with angina pectoris, prevent and treat complications after vascular stenting, and prevent and treat cardiovascular diseases;

[0180] Example 5

[0181] Objective: To explore the activation of other types of hyaluronic acid by enzymatic cleavage and commercial production of hyaluronic acid injection 1 or 2 with the therapeutic effects shown in Examples 3-4.

[0182] Methods: (1) Study the production methods of various hyaluronidases found in existing literature and the results of enzymatic cleavage of macromolecular hyaluronic acid; (2) Use independent, cooperative or contractual production of different hyaluronidases to verify their feasibility of enzymatic cleavage and activation of macromolecular hyaluronic acid; (3) Study what kind of hyaluronidase can cut and activate macromolecular hyaluronic acid to what molecular weight? What kind of enzyme cleavage terminal structure can activate small molecule hyaluronic acid to have the therapeutic effect shown by the hyaluronic acid injection of Examples 3-4? What kind of hyaluronidase residue does not cause human allergic reaction?

[0183] Results and discussion: We studied the production methods of various hyaluronidases and their methods of enzymatically cleaving macromolecular hyaluronic acid in combination with existing literature. The research results are reported as follows:

[0184] 1. In addition to the neutral human sperm acrosomal hyaluronidase PH20 (or Hyal3 or SPAM1) studied in this article, humans also have intracellular acidic hyaluronidases Hyal1 and Hyal2. Through the literature "Recombinant human hyaluronidase Hyal-1: Insect cells versus Escherichia coli as expression system and identification of low molecular weight inhibitors, Glycobiology, 17 (4): 444-53, 2007", we found that the recombinant human Hyal1 hyaluronidase produced by insect cells Drosophila Schneider-2 (DS-2) has a specific activity of 8.6U / mg and an optimal reaction pH of 3.5-4.0, but the yield is too low and is not suitable for activation and commercial production of hyaluronic acid injection with a molecular weight of 10-60KD. In addition, it is difficult to determine that the hyaluronic acid injection with a molecular weight of 10-60KD formed by the cleavage of macromolecular hyaluronic acid by recombinant human Hyal1 hyaluronidase will have the therapeutic effect shown in Examples 3-4 without human trials. We used animal cells (CHO-S cells), GC-rich pMH3, pMH4, pMH5 expression vectors and human Hyal1 and Hyal2 cDNA to produce recombinant human Hyal1 and Hyal2 proteins, and found that the activity of hyaluronidase was much less than that of PH20 (1x105 U / mg enzyme protein) we currently produce, suggesting that recombinant human Hyal1 and Hyal2 are not suitable for animal cell production.

[0185] 2. The production of neutral human sperm acrosome hyaluronidase PH20 (or Hyal3 or SPAM1) expressed in yeast can reach commercial levels, and the specific activity can reach 10,000 IU / mg enzyme protein, which is suitable for enzyme activation and commercial production of hyaluronic acid injection with the therapeutic effects shown in Examples 3-4. We used neutral human sperm acrosome hyaluronidase PH20 expressed in yeast, and after enzyme digestion, we used recombinant human hyaluronidase affinity column chromatography, precipitation, column chromatography, dialysis, ultrafiltration concentration, etc. in sequence or separately to remove the residual protein containing recombinant human hyaluronidase, and manufactured hyaluronic acid injection 2 similar to that in Example 1 that does not contain residual protein of recombinant human hyaluronidase (100 mg / 2 ml of hyaluronic acid fragments with a molecular weight of 10KD-60KD, 115-125 mM sodium chloride, and 1 mM magnesium ion), and conducted clinical studies on 38 subjects with a high incidence of various aging-related diseases. The results in Table 21 show that although the neutral human sperm acrosome hyaluronidase PH20 expressed in yeast has a low specific activity and has a certain effect on the purity of the hyaluronic acid injection, the residual protein containing recombinant human hyaluronidase can be removed to manufacture hyaluronic acid injection 2 having the therapeutic effects shown in Examples 3-4 and without allergic side effects.

[0186] Table 22: Clinical effects of hyaluronic acid injection 2 made using yeast-expressed neutral human sperm acrosome hyaluronidase PH20 on 38 subjects with a high incidence of various aging-related diseases

[0187]

[0188] 3. We used Arabidopsis thaliana to produce an oil seed expression system to produce neutral human sperm acrosome hyaluronidase PH20 fusion protein through a cooperative laboratory, and found that it can be used to produce the above-mentioned hyaluronic acid injection 2 with therapeutic effects and no allergic side effects shown in Examples 3-4, and the specific effects are shown in Table 23. However, compared with the use of animal cells to produce recombinant hyaluronidase, hyaluronidase PH20 fusion protein has low cost, high yield, low activity, and high cost for removing the residual hyaluronidase PH20 fusion protein. Compared with the high-purity saccharified recombinant human hyaluronidase produced by animal cells Chinese hamster ovary cells, it is more suitable for the production of hyaluronic acid atomizers, sprays and gels with low purity requirements for external use and therapeutic effects.

[0189] Table 23: Clinical effects of hyaluronic acid injection 2 made using plant-expressed neutral human sperm acrosome hyaluronidase PH20 on 35 subjects with a high incidence of various aging-related diseases

[0190]

[0191] 4. The hyaluronidase extracted from sheep or cattle testicles is mainly neutral sheep or cattle sperm acrosome hyaluronidase PH20, and skin allergy tests are required before human use. Although the cost is low, the purity is also low, and the cost of removing the residual sheep or cattle hyaluronidase protein contained is high. Compared with the recombinant human hyaluronidase with glycosylation of >99.0% purity produced by animal cell Chinese hamster ovary cells, it is considered that it is not suitable for producing hyaluronic acid injection 1 or 2 with high purity requirements and the therapeutic effect shown in Examples 3-4 and no allergic side effects. In addition, the hyaluronic acid fragments with a molecular weight between 10-60KD formed by the hyaluronic acid extracted from sheep or cattle testicles cleavage of macromolecular hyaluronic acid are difficult to determine without human clinical trials that there will be the therapeutic effect shown in Examples 3-4.

[0192] 5. CEDARS-SINAI MEDICAL CENTER's patent WO / 2014 / 165713 shows that small molecule hyaluronic acid less than 10KD produced by bacterial streptococci hyaluronidase does not cause inflammatory response, but small molecule hyaluronic acid greater than 10KD produced by bacterial Streptomyces hyaluronidase causes inflammatory response, which is inconsistent with the hyaluronic acid fragments with a molecular weight of 10KD-60KD produced by our use of recombinant human hyaluronidase and magnesium ions to cut and activate large molecular hyaluronic acid with therapeutic efficacy. What is important is that the residual protein of bacterial hyaluronidase may cause allergic reaction to the human body, which is not suitable for the production of hyaluronic acid injection 1 or 2 with high purity requirements and therapeutic effects and no allergic side effects as shown in Examples 3-4.

[0193] 6. The hyaluronidase in bee venom is highly allergenic. In addition to promoting the absorption of bee venom, it also causes allergic reactions in humans. The hyaluronidase extracted from bee venom and expressed by microorganisms are not suitable for producing hyaluronic acid injections 1 or 2 with high purity requirements and the therapeutic effects shown in Examples 3-4 and no allergic side effects. In addition, it is difficult to determine that the hyaluronic acid fragments with a molecular weight between 10-60KD formed by the cleavage of macromolecular hyaluronic acid by bee hyaluronidase will have the therapeutic effects shown in Examples 3-4 without human clinical trials.

[0194] 7. Leeches that suck blood secrete leech hyaluronidase, which can dissolve the skin and help leeches enter the human body to suck blood. The literature "Enzymatic production of specifically distributed hyaluronan oligosaccharides, Carbohydr Polym, 2015, 129: 194-200" and "High-yield novel leech hyaluronidase to explore the preparation of specific hyaluronan oligomers (2014), Scientific Reports 4, Article # 4471" show that the yield, enzymatic activity and cost of leech hyaluronidase fusion protein expressed in yeast can meet commercial requirements, and can cut macromolecular hyaluronic acid into small molecular hyaluronic acid with a molecular weight of 10-60KD. However, it is difficult to determine that the hyaluronic acid fragments with a molecular weight of 10-60KD formed by leech hyaluronidase cutting macromolecular hyaluronic acid will have the therapeutic effect shown in Examples 3-4 without human clinical trials. Leech hyaluronidase residues can cause allergic reactions and need to be completely removed before they can be used to produce hyaluronic acid injection 2 with the therapeutic effects shown in Examples 3-4 and no allergic side effects. We compared leech hyaluronidase with >99.0% purity of saccharified recombinant human hyaluronidase produced by animal cells Chinese hamster ovary cells and believed that leech hyaluronidase is not suitable for producing hyaluronic acid injection 1 or 2 with high purity requirements and the therapeutic effects shown in Examples 3-4 and no allergic side effects.

[0195] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein with equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of an injection solution containing small molecule hyaluronic acid, It is characterized in that The use is application in preparing medicine for treating solid tumors.

2. The use of the injection containing small molecule hyaluronic acid according to claim 1, It is characterized in that The invention is used in the preparation of a medicine for treating metastasis and recurrence of solid tumors or in the preparation of a medicine for restoring physical strength and energy after chemotherapy of solid tumors.

3. Use of the injection containing small molecule hyaluronic acid according to any one of claims 1 or 2, It is characterized in that The solid tumor is ovarian cancer, pancreatic head cancer, gastric cancer, lung cancer, colon cancer, kidney cancer or meningioma.

4. Use of the injection containing small molecule hyaluronic acid according to any one of claims 1 or 2, It is characterized in that The preparation of the injection solution containing small molecule hyaluronic acid comprises the following steps: A. Using animal cells, yeast or plants to express and produce saccharified recombinant human hyaluronidase PH20; B. preparing a macromolecular hyaluronic acid solution using a macromolecular hyaluronic acid raw material, introducing sodium chloride and magnesium ions, adding the recombinant human hyaluronidase PH20 to cut the macromolecular hyaluronic acid, and obtaining a reaction solution containing hyaluronic acid fragments with a molecular weight of 10-60KD; C. inactivating the recombinant human hyaluronidase PH20 remaining in the obtained reaction solution; D. Perform bacterial filtration, virus filtration inactivation and ultrafiltration concentration.

5. Use of the injection containing small molecule hyaluronic acid according to claim 4, It is characterized in that The preparation process also includes a step of removing the inactivated recombinant human hyaluronidase.

6. Use of the injection containing small molecule hyaluronic acid according to claim 4, It is characterized in that The purity of the saccharified recombinant human hyaluronidase PH20 in step A is >99.0%, and the purity of the macromolecular hyaluronic acid raw material in step B is >99.9%.

7. Use of the injection containing small molecule hyaluronic acid according to claim 4, It is characterized in that The molecular weight of the macromolecular hyaluronic acid raw material in step B is 800-1200KD; the concentrations of sodium chloride and magnesium ions in the macromolecular hyaluronic acid solution are 80-90mM and 1mM respectively; 20,000 units of the recombinant human hyaluronidase are added per gram of the macromolecular hyaluronic acid raw material, and the enzyme cleavage reaction is carried out at 37 degrees for 6 hours.

8. Use of the injection containing small molecule hyaluronic acid according to any one of claims 4 to 7, It is characterized in that Each 2-4 ml injection contains 100 mg of the hyaluronic acid fragment and 0-20 ug of the inactivated recombinant human hyaluronidase residue, the concentration of the magnesium ion in the injection is 1 mM, and the concentration of the sodium chloride in the injection is 115-125 mM.

9. Use of an injection solution containing small molecule hyaluronic acid according to claim 4, It is characterized in that The injection solution is used by injection into the subcutaneous fat layer of the abdomen or the painful / itchy spot or the diseased part.

10. Use of the injection solution containing small molecule hyaluronic acid according to claim 4, It is characterized in that The dosage of the injection is 1-2 times a day, and each injection contains 100 mg of the hyaluronic acid fragment with a molecular weight of 10-60 KD.